BACKGROUND: In 1995, the two-part National Institute of @entity16 and @entity64 (NINDS) Recombinant @entity1456 @entity64 Trial found that @entity1 who were treated with @entity3479 ) within three hours after the onset of symptoms of acute @entity385 were at least 30 percent more likely than @entity1 given placebo to have minimal or no disability three months after the @entity64 . It was unknown, however, whether the benefit would be sustained for longer periods. METHODS: In the NINDS Trial, a total of 624 @entity1 with @entity64 were randomly assigned to receive either @entity1456 or placebo. We collected outcome data over a period of 12 months after the occurrence of @entity64 . The primary outcome measure was a "favorable outcome," defined as minimal or no disability as measured by the Barthel index, the modified Rankin Scale, and the Glasgow Outcome Scale. We assessed the treatment effect using a global statistic. RESULTS: Using an intention-to-treat analysis for the combined results of the two parts of the trial at 6 months and 12 months, we found that the global statistic favored the @entity1456 group (odds ratio for a favorable outcome at 6 months, 1.7; 95 percent confidence interval, 1.3 to 2.3; odds ratio at 12 months, 95 percent confidence interval, 1.7; 1.2 to 2.3). The @entity1 treated with @entity1456 were at least 30 percent more likely to have minimal or no disability at 12 months than were the placebo-treated @entity1 (absolute increase in the proportion with a favorable outcome, 11 to 13 percentage points). There was no significant difference in mortality at 12 months between the @entity1456 group and the placebo group (24 percent vs. 28 percent, P=0.29). There was no interaction between the type of @entity64 identified at base line and treatment with respect to the long-term response. The rate of recurrent @entity64 at 12 months was similar in the two groups. CONCLUSIONS: During 12 months of follow-up, the @entity1 with acute @entity385 who were treated with @entity1456 within three hours after the onset of symptoms were more likely to have minimal or no disability, than the @entity1 given placebo. These results indicate a sustained benefit of @entity1456 for such @entity1 .

Effects of @entity1456 for acute @entity385 at one year. National Institute of @entity16 and @entity64 Recombinant XXXX @entity64 Study Group.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Neurological Disorders'] @entity1456 :: ('100128998', 'Gene') :: ['t-PA', 'Tissue Plasminogen Activator'] @entity3479 :: ('5327', 'Gene') :: ['tissue plasminogen activator (t-PA'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity1456 :: (100128998,Gene) :: ['Tissue Plasminogen Activator']
